| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Realized foreign currency translation loss from dissolution of subsidiaries | NaN | NaN | 0 | -7,171 |
| Change in fair value of warrant liabilities | NaN | 0 | -46,870 | -68,431 |
| Net loss | -2,869,482 | -10,110,868 | -3,037,420 | -7,279,395 |
| Impairment expense | NaN | 4,162,911 | NaN | NaN |
| Depreciation | NaN | 0 | 24,051 | 8,370 |
| Realized foreign currency translation loss from dissolution of subsidiaries | NaN | -7,171 | NaN | NaN |
| Amortization expense | 157,541 | 157,541 | 157,541 | 315,082 |
| Change in fair value of derivative warrant liability | NaN | 416,619 | NaN | NaN |
| Stock-based compensation | 139,182 | 88,277 | 52,987 | 156,203 |
| Loss on asset disposal | NaN | 0 | 102,913 | 409 |
| Change in fair value of warrant liabilities | -1,542,132 | NaN | NaN | NaN |
| Prepaid expenses | 1,018,063 | -474,553 | -15,696 | 550,785 |
| Other current assets | 12,647 | 379,158 | -84,777 | -25,103 |
| Lease liabilities | NaN | NaN | NaN | 0 |
| Accounts payable and accrued liabilities | 358,381 | -206,697 | -243,700 | 461,630 |
| Net cash used in operating activities | -4,787,220 | -5,396,822 | -2,890,025 | -6,924,643 |
| Proceeds from may 2025 public offering of common stock, net | NaN | 4,214,506 | NaN | NaN |
| Proceeds from the sale of equipment | NaN | 11,000 | NaN | NaN |
| Proceeds from december 2025 public offering of common stock, net | NaN | 53,413,572 | -2,203,724 | 4,214,506 |
| Net cash provided by investing activities | NaN | 11,000 | NaN | NaN |
| Issuance of common stock from the exercise of warrants, net | NaN | 969,000 | 0 | 1,280,000 |
| Payments on financed director and officer insurance | NaN | 39,310 | 116,145 | 292,824 |
| Proceeds from issuance of common stock under atm agreement, net of fees and offering costs | NaN | -2,136,158 | 2,203,724 | 2,010,782 |
| Proceeds from exercises of pre-funded warrants | 750 | 0 | 0 | 871 |
| Net cash provided by financing activities | 750 | 56,421,610 | -116,145 | 7,213,335 |
| Effect of foreign currency translation on cash | 28,132 | 465 | 12,670 | 5,631 |
| Net change in cash, cash equivalents, and restricted cash | -4,758,338 | 51,036,253 | -2,993,500 | 294,323 |
| Cash, cash equivalents, and restricted cash - beginning of period | 55,259,805 | 4,223,552 | 6,922,729 | NaN |
| Cash, cash equivalents, and restricted cash - end of period | 50,501,467 | 55,259,805 | 4,223,552 | NaN |
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)